Briggs Morrison - Sep 17, 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Executive Officer, Director
Signature
/s/ Michael A. Metzger, Attorney-in-fact
Stock symbol
SNDX
Transactions as of
Sep 17, 2021
Transactions value $
-$904,771
Form type
4
Date filed
9/21/2021, 04:35 PM
Previous filing
Jun 10, 2021
Next filing
Dec 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $506K +70.3K +145.36% $7.20 119K Sep 17, 2021 Direct
transaction SNDX Common Stock Sale -$1.41M -70.3K -59.24% $20.07 48.3K Sep 17, 2021 Direct F1, F2
transaction SNDX Common Stock Options Exercise $360 +50 +0.1% $7.20 48.4K Sep 20, 2021 Direct
transaction SNDX Common Stock Sale -$1K -50 -0.1% $20.00 48.3K Sep 20, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -70.3K -100% $0.00* 0 Sep 17, 2021 Common Stock 70.3K $7.20 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -50 -100% $0.00* 0 Sep 20, 2021 Common Stock 50 $7.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
F2 The sale prices ranged from $20.00 to $20.32.
F3 This option is fully vested.